Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area

Main Article Content

Craig Leonardi
Linda Stein Gold
Edward Lain
Andrea Neimann
Abby Jacobson

Keywords

Psoriasis, Plaque Psoriasis, Topical, Steroid, Retinoid, Halobetasol, Tazarotene

Abstract

Abstract not available.

References

1. Elmets CA, et al. J Am Acad Dermatol. Online ahead of print,
2020 Jul 30. doi:10.1016/j.jaad.2020.07.087.

2. Tanghetti E, et al. J Dermatolog Treat. 2019:1‑8.

3. Kircik LH, et al. J Drugs Dermatol. 2019;18(3):279-284.

4. Strober B, et al. J Am Acad Dermatol. 2020;82(1):117-122.

5. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.

6. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855‑861.

7. Basra MK, et al. Dermatology. 2015;230(1):27-33.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>